Click on the article title to read more.

Click on the article title to read more.

ObjectiveTo report 52‐week safety and efficacy of ianalumab from phase 2b dose‐finding study in patients with Sjögren's disease (SjD).MethodsPatients randomly received (1:1:1:1) ianalumab (5, 50, or 300 mg) or placebo subcutaneously every 4 weeks till week 24 (treatment period [TP]1). At week 24, patients on 300 mg were re‐randomized to continue 300 mg or receive placebo till week 52 (TP2), patients

Click on the article title to read more.

Click on the article title to read more.

Adult-onset Still's disease (AOSD) is systemic autoinflammatory disorder of unknown aetiology. Genetic studies have been limited. Here, we conducted detailed genetic and inflammatory biomarker analysis of a large AOSD cohort to investigate the underlying pathology and identify novel targets for potential treatment.

Interstitial lung disease (ILD) is a common and potentially lethal complication of systemic sclerosis (SSc). Screening by HRCT is recommended in all patients with risk factors, including early disease. Little is known on late presentations of ILD. This study aimed to characterize the incidence, risk factors and outcomes of late-onset SSc-ILD.

Macrophage activation syndrome (MAS) is a state of immune hyperactivation that can result in life‐threatening multisystem end‐organ dysfunction. Often termed a “cytokine storm”, MAS occurs among the rheumatic diseases most typically in Still's disease but also in systemic lupus erythematosus and Kawasaki disease. MAS can also accompany infection, malignancy, and inborn errors of immunity. This review

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

To characterize non-articular pain (NAP) at early RA diagnosis, the evolution over the first year of treatment, associations with active RA inflammation and impact on remission.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

ObjectiveTo describe recent trends in DMARD use for children with juvenile idiopathic arthritis (JIA) in the US.MethodsWe used commercial claims data (2000‐2022) to perform a serial cross‐sectional utilization study of children ages 1‐18 diagnosed with JIA. Initiations of conventional synthetic (cs), biologic (b), or targeted synthetic (ts) DMARDs were identified after a ≥12‐month baseline and expressed

The patient, a 60-year-old woman with osteoporosis, complained of pain in the right ankle, which spread to the perimalleolar region, and then the left ankle. No fractures were detected on the radiograph; magnetic resonance (MR) imaging showed bone edema in the cuboid–calcaneal bone heads and the left distal metadiaphyseal tibia. The patient received nonsteroidal anti-inflammatory drugs, analgesics

ObjectivesPatients with systemic lupus erythematosus (SLE) were excluded from sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) clinical trials. It is unknown whether the cardiorenal benefits of SGLT2i extend to patients with SLE and comorbid type 2 diabetes (T2D).MethodsWe performed an emulated clinical trial in an insurance‐based cohort in the U.S., evaluating SGLT2i versus dipeptidyl peptidase

Neutrophils play an important role in regulating immune and inflammatory responses in patients with rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce neutrophil activation and whether a neutrophil activation score could predict treatment response.

Click on the article title to read more.

We aimed to investigate the incidence of juvenile idiopathic arthritis (JIA) in the three geographic regions of Norway and whether potential regional incidence differences are explained by environmental or genetic factors across regions.

PurposeWe determined if metabolic syndrome, its components, and adipokines (adiponectin, leptin, Fibroblast Growth Factor‐21) were associated with response to advanced therapies among patients with rheumatoid arthritis (RA).MethodsThis study included participants with RA initiating either TNFi or non‐TNFi biologic therapies from the Comparative Effectiveness Registry to study Therapies for Arthritis

Anti–citrullinated protein antibodies (ACPA) have been detected in sputum and saliva, indicating that anti–modified protein antibodies (AMPA) can be produced at mucosal sites in patients with rheumatoid arthritis (RA). However, the body's largest mucosal compartment, the gut, has not yet been examined. We therefore investigated the presence of several AMPA (ACPA, anti–carbamylated protein antibodies

Click on the article title to read more.

Activation of type I interferon (IFN) response has been shown to correlate with disease activity in systemic sclerosis (SSc). It is currently unknown whether the tissue-specific type I IFN activation is a consequence of the response observed in blood or rather its source. Exosomes from SSc fibroblasts were recently shown to activate macrophages in vitro. Here, we aimed to determine the source of type

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

For a searchable version of these abstracts, please visit www.acrabstracts.org.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

There is a pressing need to understand the pathogenesis of histologic findings and identify the biomarkers for predicting the histologic severity in lupus nephritis (LN). This study aimed to identify the pathogenic signal pathway and elucidate urinary biomarkers for predicting the presence or severity of histologic findings in LN.

Click on the article title to read more.

Click on the article title to read more.

To compare the effectiveness of JAK inhibitors (JAKis) and biologic disease-modifying antirheumatic drugs (bDMARDs) on pain in patients with rheumatoid arthritis.

Click on the article title to read more.

The aim of this study was to evaluate the efficacy and safety of intravenous (IV) secukinumab in patients with active psoriatic arthritis (PsA).